Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02245451
Recruitment Status : Completed
First Posted : September 19, 2014
Last Update Posted : September 19, 2014
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
The primary objective of this study is to characterise the effects of tipranavir 500 mg and ritonavir 200 mg (TPV/r; given twice daily) at steady-state on the pharmacokinetics of methadone administered as a single dose in healthy adult volunteers

Condition or disease Intervention/treatment Phase
Healthy Drug: Tipranavir Drug: Ritonavir Drug: Methadone Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-centre, Open-label Study of Multiple Doses of Tipranavir 500 mg and Ritonavir 200 mg (Twice Daily) on the Pharmacokinetic Characteristics of Methadone Administered as a Single Dose in Healthy Volunteers
Study Start Date : January 2005
Actual Primary Completion Date : February 2005

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: TPV/r with methadone Drug: Tipranavir
Drug: Ritonavir
Drug: Methadone



Primary Outcome Measures :
  1. Area under the concentration-time curve for 0 to 24 hours (AUC0-24h) of methadone [ Time Frame: up to 24 hours after drug administration ]
  2. Maximum concentration (Cmax) [ Time Frame: up to 24 hours after drug administration ]
  3. Concentration at 6 hours (C6h) of methadone [ Time Frame: 6 hours after drug administration ]
  4. Area under the concentration-time curve for 0 to 12 hours (AUC0-12h) of tipranavir and ritonavir [ Time Frame: up to 12 hours after drug administration ]
  5. concentration at 12 hours (C12h) of tipranavir and ritonavir [ Time Frame: 12 hours after drug administration ]

Secondary Outcome Measures :
  1. mean residence time (MRT) [ Time Frame: up to 24 hours after drug administration ]
  2. apparent terminal half-life (t½) [ Time Frame: up to 24 hours after drug administration ]
  3. time to maximum concentration (Tmax) [ Time Frame: up to 24 hours after drug administration ]
  4. oral clearance (CL/F) [ Time Frame: up to 24 hours after drug administration ]
  5. apparent volume of distribution during the terminal elimination phase divided by the bioavailability factor (Vz/F) [ Time Frame: up to 24 hours after drug administration ]
  6. Number of patients with abnormal findings in physical examination [ Time Frame: Up to day 17 after first drug administration ]
  7. Number of patients with clinically significant changes in vital signs [ Time Frame: Up to day 17 after first drug administration ]
  8. Number of patients with abnormal changes in clinical laboratory parameters [ Time Frame: Up to day 17 after first drug administration ]
  9. Number of participants with adverse events [ Time Frame: Up to day 17 after first drug administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male or female healthy volunteers aged at least 18 to 60 years.
  • Clinically normal medical history.
  • Clinically normal findings on physical examination.
  • Clinically normal laboratory values.
  • A Body Mass Index >18.5 and <30 kg/m2.
  • Able to swallow large capsules without difficulty.
  • Capable of comprehending and communicating effectively with the investigator and staff and of providing written informed consent in accordance with ethics committee and regulatory guidelines.
  • Willing to stay in the study centre for the duration of the study.
  • Willing to abstain from ingesting substances during the study which may alter plasma study drug levels by interaction with the cytochrome P450 system.
  • Willing to abstain from alcohol for 48 hours prior to Visit 1 and for the duration of the study. In addition, Cabernet Sauvignon must not have been ingested within 15 days prior to Visit 1.
  • Willing to abstain from ingesting grapefruit and grapefruit juice for 15 days before Visit 1 and for the duration of the study.
  • Willing to abstain from ingesting Seville oranges, strawberries or strawberry extract, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) for 72 hours before the pharmacokinetic sampling days.
  • Willing to abstain from use of tobacco products for the duration of the study.
  • Urine drug screen negative for illegal non-prescription drugs.
  • Negative HIV serology.
  • Negative for Hepatitis B surface antigen and Hepatitis C

Exclusion Criteria:

  • Any clinically significant disease. (A significant disease was defined as a disease which in the opinion of the investigator may either have put the subject at risk because of participation in the study or a disease which may have influenced the results of the study or the subject's ability to participate in the study.)
  • Clinically significant abnormal baseline haematology, blood chemistry or urinalysis findings.
  • Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol, triglyceride or glucose greater than the upper limit of normal at Visit 1.
  • Treatment with prohibited medications in the thirty days before the study or during the study or ingestion of drugs of abuse.
  • Treatment with any investigational drug within 90 days of the first dose of study medication.
  • Inability to adhere to the requirements of the protocol (including active substance abuse) as assessed by the investigator.
  • Prior tipranavir use.
  • Ingestion of any known enzyme altering drug (such as phenothiazines, cimetidine, barbiturates, ketoconazole, fluconazole, clarithromycin, rifampin, steroids, and herbal medications) for thirty days prior to Visit 1.
  • Ingestion of grapefruit, grapefruit juice, and Cabernet Sauvignon within fifteen days prior to Visit 1.
  • Ingestion of Seville oranges, strawberries or strawberry extract, garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee, tea, cola, energy drinks, chocolate, etc) within 72 hours of pharmacokinetics sampling days.
  • Treatment with prescription medicines within thirty days prior to Visit 1.
  • History of gastrointestinal, hepatic, or renal disorders within 60 days prior to Visit 1.
  • Any history of alcohol or drug abuse.
  • Current use of cigarettes defined as greater than 10 cigarettes per day or rolling/pipe tobacco equivalent.
  • Blood or plasma donations within 90 days prior to Visit 1
  • Subjects with a seated systolic blood pressure either <100 mm Hg or >150 mm Hg; resting heart rate either <50 beats/min or >100 beats/min.
  • Subjects with a history of any illness or allergy that, in the opinion of the investigator, might have confounded the results of the study or posed additional risk in administering tipranavir, ritonavir or methadone to the subject.
  • Subjects who had an acute illness within two weeks prior to Visit 1.
  • Subjects who were currently taking any over-the-counter drug within fourteen days prior to Visit 1 or who were currently taking any prescription drug.
  • Hypersensitivity to tipranavir, ritonavir, or methadone.
  • Female subjects who are of reproductive potential and who were pregnant, breastfeeding, had a positive serum B-HCG at Visit 1 or 2, had not been using a barrier contraceptive method for at least three months prior to Study Day 1 or were not willing to use a reliable method of double-barrier contraception (such as diaphragm with spermicidal cream/jelly or condoms with spermicidal foam) during the study and for thirty days after completion or termination of the study.

Additional Information:
Layout table for additonal information
Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT02245451     History of Changes
Other Study ID Numbers: 1182.26
First Posted: September 19, 2014    Key Record Dates
Last Update Posted: September 19, 2014
Last Verified: September 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Ritonavir
Tipranavir
Methadone
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Antitussive Agents
Respiratory System Agents